Publications

Media, scientific publications and conference abstracts


Read about NEO and the science behind our technology


New Oncology in the media

  • Liquid biopsies transform lung cancer therapy. 2016. MedNous. April, page 13.
    pdf-Datei

  • Neue Technologie zur Tumordiagnostik. 2016. ÄrzteZeitung. No. 37-65D.
    pdf-Datei

  • Neue Technologie für die molekulare Tumordiagnostik: Nachweis aller relevanten Genveränderungen an einer Tumorprobe. 2015. Der Onkologe. Volume 21, issue 10.
    pdf file

  • Molekulare Diagnostik beim nicht-kleinzelligen Bronchialkarzinom: Neue Technologie zum raschen Nachweis aller therapierelevanten Genanomalien. 2015. Der Pneumologe. Volume 12, issue 6.
    pdf file

 

 


Selected scientific articles written by New Oncology's researchers and founders

  • Müller JN et al. Concordance between comprehensive cancer genome profiling in plasma and tumor specimens. 2017. J Thorac Oncol. Accepted manuscript available online.
    https://doi.org/10.1016/j.jtho.2017.07.014



  • Heuckmann JM et al. Comprehensive Hybrid Capture-Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH. 2017. J Thorac Oncol 12(3):e22-e24.
    https://www.ncbi.nlm.nih.gov/pubmed/28215724











  • Scheffler M et al. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. 2015. J Thorac Oncol. 10:e40-3.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Kloth M et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. 2015. Gut.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Mazières J et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. 2015. J Clin Oncol. 33:992-9.
    http://www.ncbi.nlm.nih.gov/pubmed








  • Heuckmann JM et al. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibitor in lung cancer. 2012. J Clin Oncol. 30:3417-20.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Peifer M et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 2012. Nat Genet. 44:1104-10.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Chmielecki J et al. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. 2012. Genes Chromosomes Cancer. 51:54-65.
    http://onlinelibrary.wiley.com/doi/10.1002/gcc.20930/epdf



  • Weiss J et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. 2010. Sci Transl Med. 2:62-93.
    http://www.ncbi.nlm.nih.gov/pubmed


  • Chmielecki J et al. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. 2010. Nucleic Acids Res. 38:6958-96.
    http://nar.oxfordjournals.org/content/38/20/6985.long



  • Thomas RK et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. 2006. Nat Med. 12:852-5.
    http://www.ncbi.nlm.nih.gov/pubmed

 

 

 


Conference abstracts

  • Mueller J et al. Comparison of genomic alterations derived from matched tumor tissue and liquid biopsy. WCLC 2016. Abstract P2.03b-081.
    AbstractPoster.


  • Wiest G et al. Detection of an EGFR Kinase Domain Duplication in a Lung Adenocarcinoma Patient by Liquid Biopsy using Hybrid Capture-based Next Generation Sequencing. DGHO 2016. Abstract 291.
    AbtractPoster.


  • Mueller J et al. Hybrid-capture based sequencing assays to detect novel alterations in BRAF from tissue and liquid biopsies. ESMO 2016. Abstract 2761.
    AbstractPoster.


  • Heukamp L et al. Detection of actionable genome alterations using hybrid capture based next generation sequencing technology- NEOplus and NEOliquid. ASCO 2016. Abstract e23181.
    Abstract


  • Menon R et al. Identification of Therapeutically Targetable Genomic Alterations in a cohort of patients with CUP using a Hybrid-Capture based Next Generation Sequencing Assay. AACR 2016. Abstract 152.
    Abstract. Poster.


  • Menon R et al. NEOliquid: Detection of KIF5B-RET fusions in liquid biopsy samples. ELCC 2016. Abstract 431.
    Abstract. Poster.


  • Menon R et al. Discovery of a Novel EGFR Resistance Mutation by Capture Based NGS Following AZD9291 Treatment. Oncol Res Treat 2016;39(suppl 1):120.
    Abstract. Poster.


  • Dziadziuszko R et al. Discrepancies Between ALK FISH and Capture Based NEOplus Diagnostics. WCLC 2015. Abstract 2748.
    Abstract. Poster.


  • Menon R et al. Successful AZD9291 Therapy Based on NEOliquid Detection of Circulating T790M in a Liquid Biopsy Sample. 2015. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Abstract B135.
    AbstractPoster.

 

 


Kontakt

Telephone

Office: +49.221.888.23 80

Download/More information

Information for specialists

Address

NEO New Oncology GmbH
Gottfried-Hagen-Str. 20
51105 Cologne
Germany

ImprintPrivacy policy

Newoncology.com is using cookies in order to optimize the user experience on our website. By using this site you agree to the use of cookies.

ok